{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:32:13Z","timestamp":1788877933333,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The aim of the present study was to evaluate the safety and efficacy of radionuclide therapy with [177Lu]Lu-DOTA-TATE according to our single center experience at the University of Naples Federico II. For the present analysis, we considered 21 patients with progressive, advanced, well-differentiated G1 and G2 in patients with gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs) treated with [177Lu]Lu-DOTA-TATE according to the decisions of a multidisciplinary team. All patients underwent four cycles of 7\u20138 GBq of [177Lu]Lu-DOTA-TATE every 8 weeks. A whole-body scan (WBS) was performed 4, 48, and 168 h after each treatment. The dosimetry towards the organ at risk and target lesions was calculated. For each patient, renal and bone marrow parameters were evaluated before, during, and 3 months after the end of the treatment. Follow-up data were obtained and RECIST criteria were considered as the endpoint. Among 21 patients enrolled (mean age 65 \u00b1 9 years); 17 (81%) were men and the small intestine was the most frequent location of disease (n = 12). A mild albeit significant variation (p &lt; 0.05) in both platelets and white blood cell counts among all time points was observed, despite it disappearing 3 months after the end of the therapy. According to the RECIST criteria, 11 (55%) patients had a partial response to therapy and 8 (40%) had stable disease. Only one (5%) patient had disease progression 4 months after treatment. Our data confirm that [177Lu]Lu-DOTA is safe and effective in controlling the burden disease of G1\/G2 GEP-NETs patients.<\/jats:p>","DOI":"10.3390\/curroncol31090416","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:23:04Z","timestamp":1726737784000},"page":"5617-5629","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience"],"prefix":"10.3390","volume":"31","author":[{"given":"Leandra","family":"Piscopo","sequence":"first","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-731X","authenticated-orcid":false,"given":"Emilia","family":"Zampella","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-8522","authenticated-orcid":false,"given":"Fabio","family":"Volpe","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gaudieri","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Nappi","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Di Donna","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Clemente","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-6719","authenticated-orcid":false,"given":"Antonio","family":"Varallo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-8064","authenticated-orcid":false,"given":"Mariano","family":"Scaglione","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-7658","authenticated-orcid":false,"given":"Alberto","family":"Cuocolo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-7306","authenticated-orcid":false,"given":"Michele","family":"Klain","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13139-017-0505-6","article-title":"Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors","volume":"52","author":"Kim","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_7","first-page":"342","article-title":"Theragnostic in neuroendocrine tumors","volume":"65","author":"Marini","year":"2021","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cpet.2021.03.001","article-title":"Theragnostics in Neuroendocrine Tumors","volume":"16","author":"Rodrigues","year":"2021","journal-title":"PET Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2214\/AJR.19.21123","article-title":"Therapy with 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients with Neuroendocrine Tumors","volume":"213","author":"Kendi","year":"2019","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MNM.0000000000001198","article-title":"Nephrotoxicity\/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: A systematic review","volume":"41","author":"Stolniceanu","year":"2020","journal-title":"Nucl. Med. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13306","DOI":"10.1111\/jne.13306","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1\u2013G3","volume":"35","author":"Panzuto","year":"2023","journal-title":"J. Neuroendocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40658-020-00339-2","article-title":"Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: Aspects on extrapolations and measurement time points","volume":"7","author":"Freedman","year":"2020","journal-title":"EJNMMI Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.114.148437","article-title":"Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"56","author":"Ilan","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40658-018-0224-9","article-title":"Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT","volume":"5","author":"Arsenault","year":"2018","journal-title":"EJNMMI Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40658-020-00293-z","article-title":"Personalized radiation dosimetry for PRRT-how many scans are really required?","volume":"7","author":"Freedman","year":"2020","journal-title":"EJNMMI Phys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1002\/mp.13789","article-title":"Dose point kernels for 2174 radionuclides","volume":"46","author":"Graves","year":"2019","journal-title":"Med. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmp.2021.11.001","article-title":"Overview of commercial treatment planning systems for targeted radionuclide therapy","volume":"92","author":"Tipping","year":"2021","journal-title":"Phys. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clin. Trials"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","article-title":"Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study","volume":"42","author":"Ballal","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20210896","DOI":"10.1259\/bjr.20210896","article-title":"The efficacy, toxicity and survival of salvage retreatment PRRT with 177Lu-DOTATATE in patients with progressive NET following initial course of PRRT","volume":"95","author":"Sitani","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00259-020-04873-0","article-title":"177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study","volume":"48","author":"Paganelli","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","author":"Ambrosini","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e13309","DOI":"10.1111\/jne.13309","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours","volume":"35","author":"Rinke","year":"2023","journal-title":"J. Neuroendocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12325-023-02714-8","article-title":"Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group","volume":"41","author":"Fazio","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103166","DOI":"10.1016\/j.ejmp.2023.103166","article-title":"EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy\u2014Molecular radiotherapy","volume":"116","author":"Flux","year":"2023","journal-title":"Phys. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13550-018-0443-z","article-title":"Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: A literature review","volume":"8","author":"Huizing","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Boicean, A., Boeras, I., Birsan, S., Ichim, C., Todor, S.B., Onisor, D.M., Brusnic, O., Bacila, C., Dura, H., and Roman-Filip, C. (2024). In Pursuit of Novel Markers: Unraveling the Potential of miR-106, CEA and CA 19-9 in Gastric Adenocarcinoma Diagnosis and Staging. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147898"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.bpg.2012.12.006","article-title":"Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)","volume":"26","author":"Kanakis","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:58:59Z","timestamp":1760111939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090416"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090416","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}